chufangao/CTO huggingface dataset:
Clinical trial NCT00804856: Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Official title: An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 180.0 (ACTUAL)
Number of arms: 15.0
Start date: 2008-11-27
Primary completion date: 2012-03-09
Completion date: 2021-04-23
Baseline population: Treated Set: All patients in Phase I who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason. For the Phase II part, the treated set (Phase II) was defined as all patients in Phase II who received at least a single dose of either Volasertib or LDAC.
Clinical trial NCT04028960: IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
Official title: Intranasal Insulin: A Novel Therapy for Hypoglycemia Unawareness in Type 1 Diabetes
Sponsor: HealthPartners Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding was rescinded
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-23
Primary completion date: 2020-04-08
Completion date: 2020-04-08
Baseline population: Four subjects were enrolled in the study. Two subjects started the study in the placebo arm and the other two started the study in the Humulin-R arm. During the study, each participant crossed over to the opposite arm of the study so that each subject participated in both arms of the study.
Limitations and caveats: The study team was unable to draw conclusions at this time regarding the cognitive testing performed due to abbreviated funding which led to a small number of subjects analyzed.
Clinical trial NCT03697798: A Study Exploring Whooping Cough Protection in Children and Adults
Official title: Immunological Effects of an Acellular Pertussis Booster Vaccination in Children, Young Adults and Elderly With Different Immunisation Background. An International Study in Finland, the Netherlands and the United Kingdom
Acronym: BERT
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 122.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-04-18
Primary completion date: 2020-01-14
Completion date: 2020-01-14
Clinical trial NCT05569512: Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Official title: A Phase 1/2 Trial of Uproleselan Combined With High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients With Chemotherapy Resistant Acute Myeloid Leukemia
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-06
Primary completion date: 2023-10-05
Completion date: 2023-12-06
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu BCH - Contact the Technology \& Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu
Clinical trial NCT04512430: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Official title: A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
Sponsor: Fundación GECP (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-02
Primary completion date: 2024-07-19
Completion date: 2024-07-19
Plan to share individual participant data: NO
Clinical trial NCT03818581: Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
Official title: Effect of Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes: A Randomized 3-month Clinical Trial Using a Sequential Parallel Comparison Design
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 108.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-03-15
Primary completion date: 2021-11-03
Completion date: 2021-11-03
Baseline population: Four participants in the placebo group dropped out before any baseline or follow-up data could be collected. An additional 4 participants in the treatment group dropped out, leaving only 20 participants with interpretable data.
Plan to share individual participant data: NO
Clinical trial NCT05251727: Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Official title: Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients
Sponsor: Veloxis Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 77.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-03-24
Primary completion date: 2024-06-05
Completion date: 2024-06-05
Plan to share individual participant data: NO
Clinical trial NCT03834012: Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
Official title: A Randomized, Parallel Group, Placebo-controlled, Multicenter Phase 3 Study With a PK Sub-group Study With Beclomethasone HFA at 400 μg and 800 μg Daily Doses Compared to Placebo and QVAR in Persistent Asthma.
Sponsor: Adamis Pharmaceuticals Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-02-28
Primary completion date: 2019-11-30
Completion date: 2020-04-30
Clinical trial NCT04739358: CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Official title: A Phase 1/2 Open-Label Study To Determine a Central Nervous System (CNS) Dose and Schedule Of Tepotinib Alone Or In Combination With Other Relevant Tyrosine Kinase Inhibitors (TKIs) In Adult Participants With MET-Driven NSCLC
Sponsor: Criterium, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was terminated due to lack of lack of enrollment and difficult patient population.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-25
Primary completion date: 2023-06-23
Completion date: 2023-06-23
Clinical trial NCT02545283: A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Official title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acronym: MIRROS
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
Enrollment: 447.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-30
Primary completion date: 2020-04-24
Completion date: 2020-04-24
Clinical trial NCT05395052: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Official title: A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Sponsor: Fate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study was terminated by the Sponsor.
Enrollment: 5.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-05-31
Primary completion date: 2023-08-11
Completion date: 2023-08-11
Plan to share individual participant data: NO
Clinical trial NCT02782104: A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Official title: An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Acronym: SUSTAIN-3
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1148.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-06-09
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Clinical trial NCT03850522: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Official title: Phase IIa Trial of PD-L1 Peptide Vaccination as Monotherapy in High Risk Smoldering Multiple Myeloma
Sponsor: Herlev Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient recruitment within planned enrolmentperiod.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-18
Primary completion date: 2021-03-10
Completion date: 2021-03-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04442503: A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
Official title: A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-08
Primary completion date: 2022-03-15
Completion date: 2022-04-12
Baseline population: Safety Set included all participants who were administered Investigational product (IP).
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT03797612: Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Knee Replacement in Patients With High PCS Scores
Official title: A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of Brivoligide Injection in Patients With a Pain Catastrophizing Scale Score ≥16 Undergoing Unilateral Total Knee Arthroplasty
Sponsor: Adynxx, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study initiation delayed due to COVID 19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-31
Primary completion date: 2022-01-31
Completion date: 2022-02-28
Plan to share individual participant data: NO
IPD sharing description: Individual participant data will not be made available to other researchers.
Clinical trial NCT01860404: BCAA Supplementation for Concussion
Official title: Head Injury Treatment With Healthy and Advanced Dietary Supplements (HIT HEADS): A Randomized, Placebo-controlled, Double-blinded, Therapeutic Exploratory Clinical Trial of Branched Chain Amino Acids (BCAA's) in the Treatment of Concussion
Acronym: HIT_HEADS
Sponsor: Children's Hospital of Philadelphia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 5.0
Start date: 2014-01-31
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Baseline population: Includes all 42 patients randomized
Limitations and caveats: There are several key limitations to our study that necessitate a larger, more definitive trial. Due to a combination of initially more strict inclusion criteria, and the impact of the coronavirus pandemic, our sample size was smaller than anticipated. This, combined with poorer than expected follow-up, led us to have to use alternative statistical analytic methods. We were further limited by missing data. This also necessitated the alternative analytic approach / post-hoc analysis.
Clinical trial NCT04810962: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
Official title: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study
Sponsor: Formosa Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 370.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-16
Primary completion date: 2022-07-06
Completion date: 2022-07-06
Baseline population: Intent-to-Treat Population
Plan to share individual participant data: NO
Clinical trial NCT03188185: A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
Official title: A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder
Sponsor: Alkermes, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 278.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-12
Primary completion date: 2020-02-26
Completion date: 2020-03-05
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03483103: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Official title: A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Sponsor: Juno Therapeutics, a Subsidiary of Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 74.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-27
Primary completion date: 2021-09-24
Completion date: 2022-12-01
Baseline population: 74 participants were leukapheresed.
Clinical trial NCT03535688: D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain
Official title: D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient funding to complete the study
Enrollment: 203.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-30
Primary completion date: 2024-02-07
Completion date: 2024-02-07
Clinical trial NCT04978779: A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Official title: An Open-label, Multicenter Phase 1/1b Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP152 Monotherapy or Combination Therapy in Subjects With High-risk Chronic Lymphocytic Leukemia or Richter Syndrome
Sponsor: Vincerx Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow enrollment
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-16
Primary completion date: 2023-05-26
Completion date: 2023-05-26
Clinical trial NCT03317496: Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
Official title: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).
Enrollment: 67.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-12-21
Primary completion date: 2021-06-07
Completion date: 2022-12-20
Limitations and caveats: The study was terminated since there was no need for further safety or efficacy data to be collected. The subjects having benefit from the investigational treatments have been moved to a continuation study NCT05059522
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04405102: COVID-19 Ozanimod Intervention Study
Official title: A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial
Acronym: COZI
Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit.
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-16
Primary completion date: 2022-03-14
Completion date: 2022-05-12
Plan to share individual participant data: NO
Clinical trial NCT04464460: A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
Official title: A Randomized, Double-blind, Placebo-Controlled Multicenter Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 2 Different Intravenous Doses of TAK-671 for the Treatment of Coronavirus Disease 2019 in Adults
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Business Decision (no enrollment)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-25
Primary completion date: 2020-10-30
Completion date: 2020-10-30
Plan to share individual participant data: YES
IPD sharing description: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Clinical trial NCT05295589: Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
Official title: A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Drug supply issues
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-30
Primary completion date: 2023-03-17
Completion date: 2023-03-17
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Clinical trial NCT04871113: A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
Official title: A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 62.0 (ACTUAL)
Number of arms: 10.0
Start date: 2021-06-22
Primary completion date: 2022-10-27
Completion date: 2023-09-21
Plan to share individual participant data: YES
IPD sharing description: GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
IPD time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT03483753: Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery
Official title: Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery: a Randomized and Controlled Trial
Acronym: VANCSIII
Sponsor: University of Sao Paulo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: no funding for the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-31
Primary completion date: 2023-10-02
Completion date: 2023-10-02
Plan to share individual participant data: NO
Clinical trial NCT00002874: Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Official title: A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 840.0 (ACTUAL)
Number of arms: 2.0
Start date: 1998-02-28
Primary completion date: 2015-08-31
Completion date: 2022-05-20
Baseline population: Eligible patients who have not withdrawn